VivoSeq
Other

Atrophic Vaginitis

11

Pipeline Programs↗

0

Active Trials↗

7

Companies Involved↗

Atrophic Vaginitis is an emerging landscape with 11 programs across 7 companies. The most active players are Mylan Pharmaceuticals Inc, Novo Nordisk, Respirent Pharmaceuticals Co Ltd.. 1 therapy is approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

0/100

Mech. Concentration

67/100

Completion Rate

87/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc

2 programs

Phase 3Novo Nordisk logo

Novo Nordisk

1 program

Phase 3R

Respirent Pharmaceuticals Co Ltd.

1 program

Phase 3Bayer logo

Bayer

1 program

Phase 3I

ITF Research Pharma, S.L.U.

1 program

Phase 3Pfizer logo

Pfizer

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

17

clinical trials

Completed13 · 76%
Unknown status2 · 12%
Suspended1 · 6%
Terminated1 · 6%

Clinical Trials

Trial Activity

17 trials

Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis
Completed·Novo Nordisk logoNovo Nordisk·Phase 3·NCT00431132·336 enrolled
Study Comparing Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Atrophic Vaginitis
Completed·Pfizer logoPfizer·Phase 1·NCT00167921·24 enrolled
Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial
Completed·Novo Nordisk logoNovo Nordisk·Phase 3·NCT00464971·102 enrolled
Comparison of Two Vaginal Tablets, Produced at Different Sites, in Postmenopausal Women With Atrophic Vaginitis
Completed·Novo Nordisk logoNovo Nordisk·Phase 1·NCT01085877·70 enrolled
Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency
Completed·Novo Nordisk logoNovo Nordisk·N/A·NCT01507454·1,613 enrolled
A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis
Completed·Mylan Pharmaceuticals Inc logoMylan Pharmaceuticals Inc·Phase 3·NCT02195986·366 enrolled
Efficacy and Safety of 17-Beta Estradiol in Treatment of Atrophic Vaginitis
Completed·Novo Nordisk logoNovo Nordisk·Phase 3·NCT00465192·230 enrolled
Oral Low-molecular Weight Hyaluronic Acid in the Treatment of Atrophic Vaginitis
Completed·AAGUNCO Obstetrics and Gynecology Centre·Phase 4·NCT02014428
Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis
Completed·AActavis Inc.·Phase 3·NCT03294538·663 enrolled
A Study Comparing Estradiol Vaginal Cream to Estrace® Cream in Females With Atrophic Vaginitis
Completed·AAlvogen Pine Brook LLC·Phase 3·NCT02995694·535 enrolled
Pharmacokinetic Assessment of the Absorption of Estradiol in Postmenopausal Women With Atrophic Vaginitis
Completed·Novo Nordisk logoNovo Nordisk·Phase 1·NCT01486979·58 enrolled
Clinical Study of Vaginal Lactobacilli and Estriol (Gynoflor®) for Atrophic Vaginitis in Breast Cancer Patients
Completed·MMedinova AG·Phase 1·NCT01370551·16 enrolled
Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis
Completed·Pfizer logoPfizer·Phase 3·NCT00137371·480 enrolled
Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.
Suspended·UUniversity of Vermont·Phase 1/2·NCT01122342·30 enrolled
A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis
Terminated·—·Phase 3·NCT00816556·63 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)